Hancock Jaffe Laboratories Inc. (NASDAQ:HJLI) has a beta value of 1.53 and has seen 0.32 million shares traded in the last trading session. The company, currently valued at $67.63M, closed the last trade at $8.09 per share which meant it gained $0.15 on the day or 1.89% during that session. The HJLI stock price is -118.54% off its 52-week high price of $17.68 and 38.32% above the 52-week low of $4.99. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.16 million shares traded. The 3-month trading volume is 708.00K shares.
The consensus among analysts is that Hancock Jaffe Laboratories Inc. (HJLI) is a Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Hancock Jaffe Laboratories Inc. (NASDAQ:HJLI) trade information
Sporting 1.89% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the HJLI stock price touched $8.09 or saw a rise of 0.74%. Year-to-date, Hancock Jaffe Laboratories Inc. shares have moved -6.47%, while the 5-day performance has seen it change 5.61%. Over the past 30 days, the shares of Hancock Jaffe Laboratories Inc. (NASDAQ:HJLI) have changed 34.83%. Short interest in the company has seen 0.55 million shares shorted with days to cover at 0.32.
Wall Street analysts have a consensus price target for the stock at $26.00, which means that the shares’ value could jump 68.88% from current levels. The projected low price target is $26.00 while the price target rests at a high of $26.00. In that case, then, we find that the current price level is -221.38% off the targeted high while a plunge would see the stock gain -221.38% from current levels.
Hancock Jaffe Laboratories Inc. (HJLI) estimates and forecasts
Figures show that Hancock Jaffe Laboratories Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 29.65% over the past 6 months, with this year growth rate of 79.44%, compared to 18.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -19.70% over the past 5 years.
Hancock Jaffe Laboratories Inc. is expected to release its next earnings report on June 08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Hancock Jaffe Laboratories Inc. (NASDAQ:HJLI)’s Major holders
Insiders own 12.67% of the company shares, while shares held by institutions stand at 21.37% with a share float percentage of 24.47%. Investors are also buoyed by the number of investors in a company, with Hancock Jaffe Laboratories Inc. having a total of 17 institutions that hold shares in the company. The top two institutional holders are AIGH Capital Management LLC with over 0.35 million shares worth more than $2.38 million. As of Jun 29, 2021, AIGH Capital Management LLC held 4.07% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 0.26 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $1.78 million and represent 3.04% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 29, 2021, the former fund manager holds about 0.48% shares in the company for having 40672.0 shares of worth $0.28 million while later fund manager owns 38601.0 shares of worth $0.26 million as of Mar 30, 2021, which makes it owner of about 0.45% of company’s outstanding stock.